Journal of Clinical Medicine (Apr 2021)
Safety and Feasibility of MitraClip Implantation in Patients with Acute Mitral Regurgitation after Recent Myocardial Infarction and Severe Left Ventricle Dysfunction
- Dan Haberman,
- Rodrigo Estévez-Loureiro,
- Tomas Benito-Gonzalez,
- Paolo Denti,
- Dabit Arzamendi,
- Marianna Adamo,
- Xavier Freixa,
- Luis Nombela-Franco,
- Pedro Villablanca,
- Lian Krivoshei,
- Neil Fam,
- Konstantinos Spargias,
- Andrew Czarnecki,
- Isaac Pascual,
- Fabien Praz,
- Doron Sudarsky,
- Arthur Kerner,
- Vlasis Ninios,
- Marco Gennari,
- Ronen Beeri,
- Leor Perl,
- Haim Danenberg,
- Lion Poles,
- Sara Shimoni,
- Sorel Goland,
- Berenice Caneiro-Queija,
- Salvatore Scianna,
- Igal Moaraf,
- Davide Schiavi,
- Claudia Scardino,
- Noé Corpataux,
- Julio Echarte-Morales,
- Michael Chrissoheris,
- Estefanía Fernández-Peregrina,
- Mattia Di Pasquale,
- Ander Regueiro,
- Carlos Vergara-Uzcategui,
- Andres Iñiguez-Romo,
- Felipe Fernández-Vázquez,
- Danny Dvir,
- Maurizio Taramasso,
- Mony Shuvy
Affiliations
- Dan Haberman
- Heart Center, Kaplan Medical Center, Affiliated to the Hebrew University, Jerusalem 9190501, Israel
- Rodrigo Estévez-Loureiro
- Interventional Cardiology Unit, Hospital Álvaro Cunqueiro, 36321 Vigo, Spain
- Tomas Benito-Gonzalez
- Interventional Cardiology Unit, Complejo Asistencial Universitario de Leon, 24071 Leon, Spain
- Paolo Denti
- Cardiovascular Surgery Department, San Raffaele University Hospital, 20132 Milan, Italy
- Dabit Arzamendi
- Interventional Cardiology Unit, Hospital Sant Pau i Santa Creu, 08041 Barcelona, Spain
- Marianna Adamo
- Cardiac Catheterization Laboratory, ASST Spedali Civili di Brescia, 25123 Brescia, Italy
- Xavier Freixa
- Interventional Cardiology Unit, Hospital Clinic, 08036 Barcelona, Spain
- Luis Nombela-Franco
- Hospital Clínico San Carlos, Instituto de Investigacion Sanitaria San Carlos, IdISSC, 28040 Madrid, Spain
- Pedro Villablanca
- Interventional Cardiology, The Center for Structural Heart Disease, Henry Ford Hospital, Detroit, MI 48202, USA
- Lian Krivoshei
- Department of Cardiology, Kantonsspital Baden, 5404 Baden, Switzerland
- Neil Fam
- Division of Cardiology, St. Michael’s Hospital, University of Toronto, Toronto, ON M5B 1W8, Canada
- Konstantinos Spargias
- Department of Transcatheter Heart Valves, HYGEIA Hospital, 15123 Athens, Greece
- Andrew Czarnecki
- Schulich Heart Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON M4N 3M5, Canada
- Isaac Pascual
- Department of Cardiology, Hospital Universitario Central de Asturias, 33011 Oviedo, Spain
- Fabien Praz
- Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland
- Doron Sudarsky
- Cardiovascular Institute, Baruch Padeh Medical Center, Poriya 1520800, Israel
- Arthur Kerner
- Department of Cardiology, Rambam Medical Center, and B. Rappaport Faculty of Medicine, Technion Medical School, Haifa 3109601, Israel
- Vlasis Ninios
- Department of Cardiology, Interbalkan European Medical Center, 55535 Thessaloniki, Greece
- Marco Gennari
- Department of Cardiovascular Surgery, IRCCS Centro Cardiologico Monzino, 20138 Milan, Italy
- Ronen Beeri
- Heart Institute, Hadassah-Hebrew University Medical Center, Jerusalem 91120, Israel
- Leor Perl
- Cardiology Department, Rabin Medical Center and the “Sackler” Faculty of Medicine, Tel-Aviv University, Tel-Aviv 49100, Israel
- Haim Danenberg
- Heart Institute, Hadassah-Hebrew University Medical Center, Jerusalem 91120, Israel
- Lion Poles
- Heart Center, Kaplan Medical Center, Affiliated to the Hebrew University, Jerusalem 9190501, Israel
- Sara Shimoni
- Heart Center, Kaplan Medical Center, Affiliated to the Hebrew University, Jerusalem 9190501, Israel
- Sorel Goland
- Heart Center, Kaplan Medical Center, Affiliated to the Hebrew University, Jerusalem 9190501, Israel
- Berenice Caneiro-Queija
- Interventional Cardiology Unit, Hospital Álvaro Cunqueiro, 36321 Vigo, Spain
- Salvatore Scianna
- Heart Valve Clinic, University Hospital of Zurich, 8006 Zurich, Switzerland
- Igal Moaraf
- Department of Cardiology, Kantonsspital Baden, 5404 Baden, Switzerland
- Davide Schiavi
- Cardiovascular Surgery Department, San Raffaele University Hospital, 20132 Milan, Italy
- Claudia Scardino
- Department of Cardiology, Joan XXIII University Hospital, 43005 Tarragona, Spain
- Noé Corpataux
- Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland
- Julio Echarte-Morales
- Interventional Cardiology Unit, Complejo Asistencial Universitario de Leon, 24071 Leon, Spain
- Michael Chrissoheris
- Department of Transcatheter Heart Valves, HYGEIA Hospital, 15123 Athens, Greece
- Estefanía Fernández-Peregrina
- Interventional Cardiology Unit, Hospital Sant Pau i Santa Creu, 08041 Barcelona, Spain
- Mattia Di Pasquale
- Cardiac Catheterization Laboratory, ASST Spedali Civili di Brescia, 25123 Brescia, Italy
- Ander Regueiro
- Interventional Cardiology Unit, Hospital Clinic, 08036 Barcelona, Spain
- Carlos Vergara-Uzcategui
- Hospital Clínico San Carlos, Instituto de Investigacion Sanitaria San Carlos, IdISSC, 28040 Madrid, Spain
- Andres Iñiguez-Romo
- Interventional Cardiology Unit, Hospital Álvaro Cunqueiro, 36321 Vigo, Spain
- Felipe Fernández-Vázquez
- Interventional Cardiology Unit, Complejo Asistencial Universitario de Leon, 24071 Leon, Spain
- Danny Dvir
- Jesselson Integrated Heart Centre, Shaare Zedek Medical Center, Hebrew University, Jerusalem 9103102, Israel
- Maurizio Taramasso
- Heart Valve Clinic, University Hospital of Zurich, 8006 Zurich, Switzerland
- Mony Shuvy
- Heart Institute, Hadassah-Hebrew University Medical Center, Jerusalem 91120, Israel
- DOI
- https://doi.org/10.3390/jcm10091819
- Journal volume & issue
-
Vol. 10,
no. 9
p. 1819
Abstract
Patients with severe mitral regurgitation (MR) after myocardial infarction (MI) have an increased risk of mortality. Transcatheter mitral valve repair may therefore be a suitable therapy. However, data on clinical outcomes of patients in an acute setting are scarce, especially those with reduced left ventricle (LV) dysfunction. We conducted a multinational, collaborative data analysis from 21 centers for patients who were, within 90 days of acute MI, treated with MitraClip due to severe MR. The cohort was divided according to median left ventricle ejection fraction (LVEF)—35%. Included in the study were 105 patients. The mean age was 71 ± 10 years. Patients in the LVEF p = 0.728). MR grade was significantly reduced in both groups along with an immediate reduction in left atrial V-wave, pulmonary artery pressure and improvement in New York Heart Association (NYHA) class. In-hospital and 1-year mortality rates were not significantly different between the two groups (11% vs. 7%, p = 0.51 and 19% vs. 12%, p = 0.49) and neither was the 3-month re-hospitalization rate. In conclusion, MitraClip intervention in patients with acute severe functional mitral regurgitation (FMR) due to a recent MI in an acute setting is safe and feasible. Even patients with severe LV dysfunction may benefit from transcatheter mitral valve intervention and should not be excluded.
Keywords
- mitral regurgitation
- percutaneous mitral valve repair
- acute myocardial infarction
- left ventricle dysfunction